| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,590 | 5,690 | 20.06. | |
| 5,570 | 5,670 | 19.06. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.06. | Implantica AG: Bulletin from the Annual General Meeting of Implantica AG | 99 | GlobeNewswire (Europe) | Today, June 10, 2026, the annual general meeting (the "AGM") of Implantica AG (publ) was held in Ruggell, Liechtenstein. The general meeting resolved to adopt all of the board of directors' resolution... ► Artikel lesen | |
| 09.06. | Implantica announces launch of 20th RefluxStop Center of Excellence in Spain, part of a world-renowned US hospital group | 293 | PR Newswire | VADUZ, Liechtenstein, June 9, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop... ► Artikel lesen | |
| IMPLANTICA Aktie jetzt für 0€ handeln | |||||
| 22.05. | Implantica publishes Interim Report January - March 2026 (Q1) | 412 | PR Newswire | VADUZ, Liechtenstein, May 22, 2026 /PRNewswire/ --
Substantially Advancing Clinical Outcomes & Economic Impact of RefluxStopSignificant events in the first quarter of 2026Secured over... ► Artikel lesen | |
| 21.05. | Notice of Annual General Meeting of Implantica AG | 345 | PR Newswire | VADUZ, Liechtenstein, May 21, 2026 /PRNewswire/ -- The depository receipt holders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby invited to attend the annual general meeting to... ► Artikel lesen | |
| 21.05. | Implantica announces publication of a new health economics study showing RefluxStop's superior cost-effectiveness in the treatment of GERD in the Italian Healthcare System | 7 | Cision News | ||
| 20.05. | Implantica submits final response to FDA in the PMA application for RefluxStop for U.S. market approval | 260 | PR Newswire | VADUZ, Liechtenstein, May 20, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including... ► Artikel lesen | |
| 19.05. | Implantica announces new breakthrough long-term RefluxStop data on severe sufferers presented at DDW 2026 | 996 | PR Newswire | VADUZ, Liechtenstein, May 19, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop... ► Artikel lesen | |
| 19.05. | IMPLANTICA: RefluxStop gains momentum at DDW 2026 | 2 | Cision News | ||
| 18.05. | Implantica presents the first quarter (Q1 2026) on May 22 at 15:00 CET | 281 | PR Newswire | VADUZ, Liechtenstein, May 18, 2026 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the first quarter 2026 at 15:00 CET on May 22. The interim report for the first... ► Artikel lesen | |
| 06.05. | Implantica publishes Annual Report 2025 | 321 | PR Newswire | VADUZ, Liechtenstein, May 6, 2026 /PRNewswire/ -- Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report... ► Artikel lesen | |
| 21.04. | Implantica announces landmark RefluxStop study of 602 patients across 22 European centers, with up to 6.75-year follow-up, published in Nature's Scientific Reports | 422 | PR Newswire | VADUZ, Liechtenstein, April 21, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop... ► Artikel lesen | |
| 26.03. | Implantica publishes Year-end Report, January - December 2025 (Q4) | 353 | PR Newswire | VADUZ, Liechtenstein, March 26, 2026 /PRNewswire/ --
RefluxStop US Launch Coming Closer, pending FDA approvalSignificant events in the fourth quarter FDA completed six pre-approval... ► Artikel lesen | |
| 25.02. | Implantica AG: Implantica publishes Year-end Report, January - December 2025 (Q4) | 475 | GlobeNewswire (Europe) | RefluxStop® US Launch Coming Closer, pending FDA approval
Significant events in the fourth quarter
FDA completed six pre-approval inspections during the quarter - including manufacturing sites,... ► Artikel lesen | |
| 18.02. | Implantica presents the Year-end Report (Q4 2025) on February 25 at 15:00 CET | 431 | PR Newswire | VADUZ, Liechtenstein, Feb. 18, 2026 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the Year-end Report (Q5 2025) at 15:00 CET on February 25. The Year-end Report... ► Artikel lesen | |
| 27.01. | Implantica announces major public tender wins in Italy securing over EUR 1.2 million funding for RefluxStop | 640 | PR Newswire | VADUZ, Liechtenstein, Jan. 27, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device... ► Artikel lesen | |
| 10.12.25 | Implantica strengthens market expansion as Italy's leading Careggi University Hospital in Florence introduces RefluxStop | 543 | PR Newswire | VADUZ, Liechtenstein, Dec. 10, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device... ► Artikel lesen | |
| 25.11.25 | Implantica: RefluxStop 'Best in Class' at Japan Foregut Conference as 5-Year Data and Extensive Safety Cohort is Presented to 120 Leading Surgeons | 403 | PR Newswire | VADUZ, Liechtenstein, Nov. 25, 2025 /PRNewswire/ -- Implantica AG (publ), a medtech company at the forefront of introducing advanced technology into the body, announced today that its innovative... ► Artikel lesen | |
| 11.11.25 | Implantica: RefluxStop takes center stage at 2025 European Foregut Society meeting | 574 | PR Newswire | VADUZ, Liechtenstein, Nov. 11, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique... ► Artikel lesen | |
| 31.10.25 | Implantica publishes Interim Report January - September 2025 (Q3) | 479 | PR Newswire | VADUZ, Liechtenstein, Oct. 31, 2025 /PRNewswire/ --
RefluxStop® Nears FDA Approval - Strong Momentum Toward US Market Entry
Significant events in the... ► Artikel lesen | |
| 27.10.25 | Implantica presents the third quarter 2025 on October 31 at 15:00 CET | 398 | PR Newswire | VADUZ, Liechtenstein, Oct. 27, 2025 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the third quarter 2025 at 15:00 CET on October 31. The interim report... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 39,610 | +0,76 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Fresenius auf "Buy" mit einem Kursziel von 55 Euro belassen. Die Bedenken im Deutschen Bundesrat bezüglich staatlicher Kürzungen... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,700 | -1,36 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 34,230 | +0,18 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 24,940 | +0,40 % | Carl Zeiss Meditec AG: ZEISS announces strategic collaboration with Envision Health Technologies to advance glaucoma care with virtual reality-based function testing | ZEISS Medical Technology and Envision Health Technologies will collaborate to advance the next generation of patient-accessible, software-driven visual function testing while maintaining... ► Artikel lesen | |
| ECKERT & ZIEGLER | 15,560 | +0,19 % | Was Insider bei Eckert&Ziegler zum Wochenstart bereits wissen: 3,9% Plus und das könnte erst der Anfang sein - Bereiten Sie sich auf Montag vor | ||
| UNITEDHEALTH | 345,40 | -1,03 % | Dividendenbekanntmachungen (15.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A&W FOOD SERVICES OF CANADA INC CA0002251027 0,48 CAD 0,2966 EUR AEGON LTD ADR US0076CA1045 0,2468 USD 0,2134 EUR AGROB IMMOBILIEN... ► Artikel lesen | |
| DRAEGERWERK | 84,30 | +1,20 % | JEFFERIES stuft Draegerwerk auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Drägerwerk von 73 auf 90 Euro angehoben, aber die Einstufung auf "Hold" belassen. Die Margenentwicklung des Spezialisten... ► Artikel lesen | |
| GERRESHEIMER | 25,600 | -1,31 % | Gerresheimer-Aktie: Wissen die Insider mehr? | Die Gerresheimer-Aktie hat sich in den vergangenen Monaten eindrucksvoll erholt. Nach dem Absturz auf rund 16 € Ende Februar notiert sie inzwischen wieder deutlich höher. Am Montag startet sie aktuell... ► Artikel lesen | |
| INTUITIVE SURGICAL | 356,10 | +0,49 % | Intuitive Surgical (ISRG) Promotes Taylor Patton to Chief Commercial and Marketing Officer | ||
| MEDTRONIC | 69,68 | -0,11 % | Medtronic plc - 10-K, Annual Report | ||
| THERMO FISHER | 402,10 | -0,22 % | If You Invested $100 In Thermo Fisher Scientific Stock 15 Years Ago, You Would Have This Much Today | ||
| TELADOC HEALTH | 6,930 | -1,06 % | Teladoc Health extends rally to seventh straight session | ||
| STRATEC | 18,180 | -0,22 % | EQS-PVR: STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: STRATEC SE
STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| RHOEN-KLINIKUM | 12,500 | 0,00 % | Tag des Cholesterins am 12. Juni 2026 / Experten am RHÖN-KLINIKUM Campus Bad Neustadt appellieren: "Jeder sollte seinen LDL-Wert kennen" | Bad Neustadt a.d. Saale (ots) - Hohe Blutfette erhöhen das Risiko für Herzinfarkt, Schlaganfall und Durchblutungsstörungen der GefäßeHerz-Kreislauf-Erkrankungen sind nach wie vor die häufigste Todesursache... ► Artikel lesen | |
| OTTOBOCK | 50,30 | 0,00 % | JEFFERIES stuft Ottobock auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Ottobock auf "Buy" mit einem Kursziel von 83 Euro belassen. Der Verkauf des Rollstuhlgeschäfts komme erwartungsgemäß, da... ► Artikel lesen |